Related posts
Tech fades in mixed tradingStocks, oil and cryptos rallyOil slides, but stocks hold on China’s weaknessThis summary was created by AI, based on 3 opinions in the last 12 months.
Gilead Sciences Inc. has garnered attention recently due to its performance, having just reported earnings that exceeded expectations, hitting 52-week highs as it attempts to break out of a long period of consolidation lasting nine years. While some experts appreciate the recent bounce in share prices, others express concerns about the valuation, suggesting that the company's business fundamentals do not fully justify current stock levels. The company's historic successes with Hepatitis C and HIV treatments have created a unique situation where their past triumphs impact future growth prospects, as these therapies are not continuously required by patients. Nevertheless, Gilead offers a decent dividend, which may appeal to income-focused investors despite apprehensions regarding long-term growth potential.
The business isn't worth as much as the stock is selling, even though shares have recently bounced back.
High flyer because of Hep C, so successful it isn't needed on an ongoing basis. Its HIV drug was equally successful. Ironically, success impacted growth of those drugs negatively. Decent dividend.
Healthcare is down 2% year. He likes the devices in HC, with Stryker his top pick. Surgeries are coming back, and the company has a new suite of products coming.
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
Chart pattern indicating weakness in the company.
Risk lower than the past year.
$60 share price a good time to buy.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
It is a biotech company well known for a cure for Hepatitis C which is off patent now. It made several acquisitions and has built out an HIV franchise. He needs to see execution on the oncology platform and elsewhere.
No new drugs or trials. Doing nothing interesting. Prefers Eli Lilly.
Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q
In the last year, 2 stock analysts published opinions about GILD-Q. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..
Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.
On 2025-02-18, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $105.25.
Hitting 52-week highs. Caught his attention because last week they beat top and bottom lines. After consolidating 9 years, it's starting to break out. Doesn't know this well enough to see if this breakout will hold, but worth watching.